Levalbuterol Inhalation

Introduction Overview

Generic Name

levalbuterol inhalation

Brand Name

Xopenex HFA

Dosage Form

inhaler (HFA aerosol), nebulizer solution (concentrate)

Drug Class

Adrenergic bronchodilators

Pharmacokinetics

Absorption:
Levalbuterol inhalation via the Xopenex HFA inhaler delivers the active enantiomer of albuterol directly to the lungs, enabling rapid onset of bronchodilation. Upon inhalation, levalbuterol is absorbed across the respiratory mucosa into systemic circulation. The pulmonary bioavailability is influenced by inhalation technique, particle size, and device efficiency. The inhaler provides rapid delivery with onset of action typically within 15 minutes, peaking at 30-60 minutes. The nebulizer solution, when aerosolized, also allows for pulmonary absorption but may result in slightly slower systemic absorption compared to inhaler use due to differing particle dispersion and patient inhalation variability. Food intake does not significantly affect absorption due to direct pulmonary delivery.

Distribution:
Once absorbed, levalbuterol distributes widely throughout the body via systemic circulation. It exhibits moderate plasma protein binding (approximately 16-27%) primarily to serum albumin. The volume of distribution is estimated between 156 to 273 liters, suggesting distribution into tissues outside the vascular compartment. Distribution to lung tissue is favored due to direct delivery and local retention within airway smooth muscle, contributing to its therapeutic actions. Levalbuterol crosses the placental barrier and may be present in breast milk; thus, caution is advised in pregnant or nursing patients. CNS penetration is limited, minimizing central adrenergic side effects.

Metabolism:
Levalbuterol undergoes hepatic metabolism primarily via sulfate conjugation and to a lesser extent by other Phase II metabolism pathways. Unlike racemic albuterol, levalbuterol’s metabolism results predominantly in inactive sulfate conjugates, reducing potential for active metabolite-related effects. The R-enantiomer present in racemic formulations is not a component here, which is theorized to reduce side effects. Cytochrome P450 enzymes have minimal involvement, leading to low potential for hepatic drug interactions. The metabolic clearance can be affected by hepatic impairment but is generally not significant at therapeutic doses.

Elimination:
The elimination half-life of levalbuterol after inhalation is approximately 3.3 to 4.2 hours. The clearance is primarily renal, with about 60-70% of the administered dose excreted unchanged or as conjugated metabolites in the urine within 24 hours. Renal function impairment may prolong elimination, necessitating dosage adjustments in severe cases. The drug’s clearance profile supports dosing every 4 to 6 hours as clinically indicated. Minimal fecal excretion occurs. The elimination kinetics contribute to the drug’s short-acting bronchodilator classification, allowing for rescue and prevention of bronchospasm.

Dosage Forms

Available Dosage Forms:
Xopenex HFA is available as a metered-dose inhaler (MDI) utilizing hydrofluoroalkane (HFA) propellant delivering aerosolized levalbuterol. Each inhaler provides a specific number of actuations, typically 60 or 200 sprays per canister. The dose per actuation is 45 mcg of levalbuterol base.

Additionally, Xopenex is available as a nebulizer concentrate solution packaged in single-use plastic vials. The concentrate is colorless and clear, designed to be diluted with a specified volume of normal saline prior to nebulization.

Dosages for Adults and Adolescents:
For the MDI inhaler: the usual dosage is two inhalations (each 45 mcg) every 4 to 6 hours as needed for bronchospasm relief. In some cases, a single inhalation may suffice. The maximum recommended dose is generally 4 inhalations every 4 hours.

For nebulizer solution: doses range from 0.31 mg to 1.25 mg nebulized three times daily, with individual titration based on clinical response and severity of symptoms.

Specific Patient Populations:
Children 4 years and older may use the MDI inhaler with proper supervision and technique. Children under 4 years are not recommended to use the inhaler due to coordination requirements.

Nebulizer solution is indicated for children 6 years and older; safety and efficacy below this age have not been established.

Dose adjustments may be necessary in patients with cardiovascular disease, hyperthyroidism, diabetes, or seizure disorders. In elderly patients, standard dosing applies but monitoring for side effects is prudent.

Special considerations include priming of the inhaler before first use and after periods of non-use exceeding three days. Nebulizer solution must be diluted correctly and used immediately after preparation.

Mechanism Of Action

Levalbuterol is the pharmacologically active R-enantiomer of racemic albuterol, functioning as a selective beta-2 adrenergic receptor agonist. At the molecular level, levalbuterol binds to beta-2 adrenergic receptors located predominantly on the smooth muscle cells lining the bronchial airways. This binding induces a conformational change activating adenylate cyclase through Gs-protein coupling.

Activated adenylate cyclase catalyzes the conversion of ATP to cyclic AMP (cAMP), which serves as a second messenger to activate protein kinase A (PKA). PKA phosphorylates various intracellular proteins leading to decreased intracellular calcium concentrations and subsequent relaxation of bronchial smooth muscle fibers. This relaxation reduces airway resistance and ameliorates bronchospasm, thereby facilitating improved airflow and oxygen delivery.

In addition to muscle relaxation, levalbuterol inhibits the release of bronchoconstrictive mediators from mast cells and decreases vascular permeability, reducing airway inflammation and edema to a certain extent. It also enhances mucociliary clearance, assisting in the removal of airway secretions.

Clinically, the efficacy of levalbuterol is enhanced over racemic albuterol due to the absence of the S-enantiomer, which has been implicated in pro-inflammatory and bronchoconstrictive effects. Thus, levalbuterol provides bronchodilation with a lower incidence of tachycardia, tremor, and other beta agonist-related adverse effects. Clinical studies demonstrate rapid onset of action within 15 minutes and peak effects at 30 to 60 minutes, making it effective for both prevention and relief of acute bronchospasm in asthma and COPD patients.

Pharmacological Actions

Selective stimulation of beta-2 adrenergic receptors in bronchial smooth muscle leading to relaxation and bronchodilation.
Activation of adenylate cyclase enzyme resulting in increased intracellular cyclic AMP levels.
Inhibition of mediator release from mast cells, reducing local bronchial inflammation.
Decrease in airway vascular permeability, leading to reduced edema and mucus secretion.
Enhancement of mucociliary clearance from the respiratory tract.
Rapid onset of action within 15 minutes post inhalation.
Short duration of bronchodilation generally lasting 4 to 6 hours.
Reduced side effects profile compared to racemic albuterol due to absence of S-enantiomer.
Minimal beta-1 adrenergic receptor activity, reducing cardiac stimulant effects.
Suitable for both rescue treatment of acute asthma exacerbations and prophylaxis.
Low potential for causing tolerance or receptor desensitization at recommended doses.
Improvement in pulmonary function tests such as FEV1 in obstructive airway diseases.
FDA-approved for use in adults and children aged 4 years and older (inhaler), and 6 years and older (nebulizer).

Therapeutic Or Clinical Uses

Treatment and prevention of bronchospasm in asthma patients aged 4 years and older.
Management of reversible airway obstruction in chronic obstructive pulmonary disease (COPD).
Relief of bronchospasm induced by exercise or allergens.
Acute management of asthma exacerbations as a rescue inhaler therapy.
Off-label use may include prevention of bronchospasm associated with bronchitis, bronchiectasis, and emphysema.
Adjunct therapy in combination with corticosteroids and other asthma controllers.
Treatment of airway hyper-responsiveness in pediatric patients managing asthma.
Use in patients intolerant to racemic albuterol with fewer systemic side effects.
Inhalation route allows targeted pulmonary drug delivery, optimizing therapeutic effect with minimal systemic exposure.
Nebulizer solution indicated for patients who cannot use metered-dose inhalers effectively.
Short-acting bronchodilator for intermittent symptom control or acute intervention.

Side Or Adverse Effects

Tachycardia or palpitations due to systemic beta-adrenergic stimulation.
Tremors and nervousness are common, especially in sensitive individuals.
Dizziness and headache following inhalation.
Chest pain or tightness which may indicate cardiovascular stress.
Worsening bronchospasm or paradoxical bronchospasm requiring immediate medical attention.
Hypokalemia manifesting as leg cramps, muscle weakness, or arrhythmias.
Sore throat, throat irritation, and nasal congestion.
Vomiting and gastrointestinal discomfort in some patients.
Rare allergic reactions including hives, facial swelling, and anaphylaxis.
Fluttering sensations or irregular heartbeats (arrhythmias).
Muscle cramps or numbness/tingling related to electrolyte imbalance.
Possible worsening of pre-existing cardiac conditions.
Increased blood pressure or hypertension may occur in susceptible patients.
Restlessness or insomnia, especially if taken late in the day.
Respiratory infections or upper respiratory tract irritation occasionally reported.

Precautions

Use with caution in patients with cardiovascular diseases such as coronary artery disease, arrhythmias, and heart failure.
Screen patients for history of hypertension or ischemic heart conditions prior to initiation.
Monitor blood pressure and heart rate periodically during treatment.
Use cautiously in patients with seizure disorders or hyperthyroidism.
Consider risk-benefit ratio in diabetic patients due to potential for hyperglycemia.
Avoid abrupt discontinuation to prevent rebound bronchospasm.
Ensure proper inhaler technique and device handling to maximize efficacy and reduce side effects.
Supervise pediatric patients during administration to ensure correct dosing.
Avoid concurrent use with other sympathomimetic drugs unless directed by a physician.
Prime the inhaler before first use and if unused for more than 3 days to ensure accurate dosing.
Store medication away from heat and moisture to preserve integrity.
Warn patients against overuse that may lead to severe tachycardia or hypokalemia.
Use caution in patients with QT prolongation or receiving other QT-prolonging agents.
Pregnancy and lactation should be considered carefully; use only if benefit justifies potential risk.
Educate patients on recognizing signs of paradoxical bronchospasm requiring immediate medical care.

Warnings

Do not use Xopenex HFA if allergic to levalbuterol or albuterol to avoid severe allergic reactions.
Seek medical attention immediately if asthma symptoms worsen or if wheezing, choking, or breathing difficulties occur after use.
Overuse or abuse may result in life-threatening cardiac side effects including arrhythmias and hypertension.
Notify healthcare provider promptly if signs of hypokalemia appear such as muscle weakness or irregular heartbeat.
Pregnant or breastfeeding women should consult healthcare providers before use.
Avoid exposure to factors that exacerbate asthma such as cold dry air, allergens, smoke, and dust.
Discontinue use and seek emergency care if paradoxical bronchospasm occurs.
Patients should not exceed prescribed dose or frequency to prevent overdose risks.
Store inhaler and nebulizer concentrate away from open flames or high heat to prevent explosion.
Do not puncture or burn empty canisters due to risk of explosion.
Regular follow-up is essential to assess asthma control and modify therapy as needed.
Inform all healthcare providers about levalbuterol use prior to surgical procedures or imaging studies.
Patients with certain hereditary conditions, including prolonged QT syndrome, should use with caution.
Xopenex HFA is not indicated for children under 4 years (inhaler) or under 6 years (nebulizer).

Contraindication

Known hypersensitivity or allergy to levalbuterol or any component of the formulation.
Allergy to racemic albuterol (e.g., formulations such as Accuneb, ProAir, Proventil, Ventolin).
History of severe hypersensitivity reactions to beta-2 adrenergic agonists.
Use in pediatric patients below 4 years of age for the inhaler formulation due to safety concerns.
Use in pediatric patients below 6 years of age for nebulizer concentrate due to lack of established safety.
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.
Concurrent treatment with tricyclic antidepressants or other sympathomimetic drugs without medical supervision.
Severe tachyarrhythmias or uncontrolled cardiac arrhythmias.
Patients with hypertrophic obstructive cardiomyopathy at risk of exacerbation.
Use should be avoided in patients with hypersensitivity to inhaler propellants or preservatives.
Contraindicated in patients with untreated thyrotoxicosis due to risk of cardiac complications.

Drug Interactions

Concomitant use with monoamine oxidase inhibitors (MAOIs) can lead to hypertensive crisis.
Tricyclic antidepressants may potentiate cardiovascular adverse effects such as tachycardia and arrhythmias.
Beta-blockers (selective and non-selective) may reduce or antagonize bronchodilator effects.
Diuretics such as thiazides and loop diuretics may potentiate hypokalemia when combined with levalbuterol.
Other sympathomimetic bronchodilators increase risk of additive beta-adrenergic side effects.
Digoxin levels may be affected by concurrent use due to electrolyte changes (hypokalemia).
Corticosteroids may enhance hypokalemia associated with beta-agonist therapy.
MAOIs or tranylcypromine use within 14 days increases risk of cardiovascular toxicity.
Drug interactions with other medications prolonging QT interval may increase arrhythmia risk.
Antidepressants such as SSRIs and SNRIs may interact at adrenergic pathways requiring monitoring.
Combination with ketoconazole or other CYP450 inhibitors has minimal interaction but monitor clinically.
Use caution with other drugs causing CNS stimulation to avoid exacerbated nervousness or tremors.
Caffeine intake may enhance sympathomimetic effects, increasing shakiness and heart rate.
Herbal supplements with adrenergic activity (e.g., ephedra) may potentiate cardiovascular effects.
Inform healthcare professionals of all over-the-counter, prescribed, and herbal medications.

Preparations Of The Drug

Xopenex HFA Metered Dose Inhaler (MDI) delivering 45 mcg of levalbuterol base per inhalation with hydrofluoroalkane (HFA) propellant.
Metered dose inhaler available in canisters containing 60 or 200 inhalations.
Xopenex Nebulizer Concentrate solution in single-use plastic vials containing 0.31 mg, 0.63 mg, or 1.25 mg of levalbuterol per vial, clear and colorless.
Nebulizer concentrate intended for dilution with normal saline prior to administration via jet nebulizer.
Inhaler packaged with mouthpiece cover and an instruction leaflet.
Nebulizer vials packaged individually within protective foil pouches to preserve stability.
Inhaler formulation includes excipients such as ethanol, oleic acid, and HFA-134a as propellant.
Nebulizer solution contains sterile water for injection and diluent requirements as per label instructions.
Each unit dose vial for nebulizer is intended for single use and must be discarded after use.
Inhaler requires priming by actuating sprays into air before initial use and after 3 days of nonuse.
Storage instructions for inhaler include room temperature with protection from extreme heat or freezing.
Nebulizer concentrate must be stored in unopened foil pouch at room temperature, away from moisture.
Packaging includes dosing counter on inhaler to track remaining doses.
Preparation instructions emphasize removing canister before cleaning inhaler mouthpiece with warm water.
Patient information and instructions for use accompany all formulations for safe and effective administration.